Development and clinical feasibility study of a brief version of an addiction‐focused phenotyping battery in females receiving buprenorphine for opioid use disorder

INTRODUCTION: We aimed to streamline the NIDA Phenotyping Assessment Battery (PhAB), a package of self‐report scales and neurobehavioral tasks used in substance use disorder (SUD) clinical trials, for clinical administration ease. Tailoring the PhAB to shorten administration time for a treatment setting is critical to expanding its acceptability in SUD clinical trials. This study's primary objectives were to develop a brief version of PhAB (PhAB‐B) and assess its operational feasibility and acceptability in a female clinical treatment sample. METHODS: Assessments of the original PhAB were evaluated along several criteria to identify a subset for the PhAB‐B. Non‐pregnant females (N=55) between ages 18–65, stabilized on buprenorphine for opioid use disorder (OUD) at an outpatient addiction clinic, completed this abbreviated battery remotely or after a provider visit in clinic. Participant satisfaction questions were administered. REDCap recorded the time to complete PhAB‐B measures. RESULTS: The PhAB‐B included 11 measures that probed reward, cognition, negative emotionality, interoception, metacognition, and sleep. Participants who completed the PhAB‐B (N =55) were 36.1 ± 8.9 years of age, White (54.5%), Black (34.5%), and non‐Latinx (96.0%). Most participants completed the PhAB‐B remotely (n = 42, 76.4%). Some participants completed it in‐person (n = 13, 23.6%). PhAB‐B mean completion time was 23.0 ± 12.0 min. Participant experiences were positive, and 96% of whom reported that they would participate in the study again. CONCLUSION: Our findings support the clinical feasibility and acceptability of the PhAB‐B among a female opioid use disorder outpatient addiction treatment sample. Future studies should assess the PhAB‐B psychometric properties among broader treatment samples.